PRINCETON, N.J., Oct. 15 /PRNewswire/ -- Weekly Digest (http://www.bullmarket.com/digest), a free investment research publication, announced the publication of a special report on investment opportunities in connection with the H1N1 "Swine Flu" Outbreak, including updated outlooks for Alpha Pro Tech (AMEX:APT), Novavax (NASDAQ:NVAX), Generex Biotechnology (NASDAQ:GNBT), Inovio Biomedical (AMEX:INO), AstraZeneca (NYSE:AZN) and several others.
After posting large gains throughout 2009, swine flu stocks are seeing their largest pullback yet. For investors looking to position their portfolios for flu season, there are more ways to trade the flu than ever. Investors have large-cap pharmaceutical plays to choose from, and some of the more volatile, small-cap names have proven the efficacy of their drugs, while others are too far behind in their clinical trials to capitalize on the current pandemic.
To receive a free, 23-page report offering in depth analysis of the various participants in the vaccine and antiviral market, as well as some peripheral plays focusing directly on the impact of the current H1N1 swine flu pandemic, please visit the following link: http://www.bullmarket.com/digest/signup.php?refer=pr2_swineflu The report covers these topics and more: -- Which small-cap swine flu plays have a real chance of benefiting in the event of a serious H1N1 outbreak and which are riding on the hype? -- How much do N-95 respirators contribute to Alpha Pro Tech's overall business? Is Alpha Pro Tech stock likely to hold onto its gains, even if the swine flu threat subsides? -- What sets Novavax apart from other flu-focused small-caps and might a long-term investment in Novavax be justified? What red flag do Novavax investors need to be aware of? -- Is Generex a real swine flu play? What do Generex investors need to know about the company's swine flu efforts? -- Why might Inovio's animal testing results be more important than some investors realize? When can investors expect to next see material news related to the company's swine flu efforts? -- How much is swine flu vaccine revenue expected to contribute to AstraZeneca's total revenue? What factors could limit AstraZeneca's efforts in the vaccine market? Is it among the large-cap pharmaceutical firms best positioned to address the swine flu threat? About Weekly Digest: Weekly Digest is a free publication offering first-rate stock research, analysis, and commentary that is independently published by leading investment services. Subscribers receive a weekly newsletter as well as regular Special Reports, such as the new report Investor Essentials: Picking Winners for Pandemic Profits.
NOTE: This release was published by Indie Research Advisors, LLC, a registered investment advisor with CRD #131926. Interested parties may visit adviserinfo.sec.gov for additional information. Past performance does not guarantee future results. Investors should always research companies and securities before making any investments. Nothing herein should be construed as an offer or solicitation to buy or sell any security.
CONTACT: Marcia Martin, +1-888-278-5515 DATASOURCE: Indie Research Advisors, LLC CONTACT: Marcia Martin of Indie Research Advisors, LLC, +1-888-278-5515 Web Site: http://www.bullmarket.com/digest
|